Nautilus Biotechnology, Inc.
Business
Nautilus Biotechnology is a development-stage life sciences company creating a platform technology to measure and quantify the proteome at scale. The company develops the Nautilus Voyager platform, which integrates instrumentation, consumables (flow cells and affinity reagents), and cloud-based software to enable single-molecule proteomic analysis through its proprietary Iterative Mapping method. Nautilus addresses research, translational, and eventual clinical applications in proteomics, serving academic institutions, pharmaceutical and biotechnology companies, and research organizations initially through fee-for-service analysis and planned instrument commercialization beginning late 2026.
Summary from 10-K filed 2026-02-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 41 | 50 | 47 | 38 | 29 | |
| General and administrative | 26 | 31 | 29 | 26 | 21 | |
| Total operating expenses | 67 | 81 | 76 | 64 | 50 | |
| Interest income | 8 | 11 | 13 | 6 | 329,000 | |
| Other expense | −32,000 | −84,000 | −73,000 | −122,000 | −146,000 | |
| Total other income | 8 | 11 | 12 | 6 | 183,000 | |
| Net loss | −59 | −71 | −64 | −58 | −50 | |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | −0.47 | −0.56 | −0.51 | −0.46 | −0.6 | |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | −0.47 | −0.56 | −0.51 | −0.46 | −0.6 | |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares) | 126 | 125 | 125 | 125 | 84 | |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) | 126 | 125 | 125 | 125 | 84 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 12 | 28 | 19 | 115 | 186 | |
| Short-term investments | 91 | 102 | 154 | 70 | 160 | |
| Prepaid expenses and other current assets | 3 | 3 | 3 | 3 | 3 | |
| Total current assets | 106 | 133 | 177 | 187 | 349 | |
| Property and equipment, net | 3 | 4 | 4 | 4 | 2 | |
| Operating lease right-of-use assets | 28 | 28 | 33 | 29 | 29 | |
| Long-term investments | 53 | 76 | 91 | 129 | — | |
| Other long-term assets | 1 | 1 | 1 | 1 | 997,000 | |
| Total assets | 191 | 243 | 306 | 350 | 398 | |
| Accounts payable | 943,000 | 987,000 | 2 | 1 | 2 | |
| Accrued expenses and other liabilities | 3 | 3 | 4 | 4 | 3 | |
| Current portion of operating lease liability | 4 | 4 | 4 | 2 | 970,000 | |
| Total current liabilities | 8 | 8 | 9 | 7 | 6 | |
| Operating lease liability, net of current portion | 26 | 26 | 31 | 28 | 29 | |
| Total liabilities | 34 | 34 | 40 | 35 | 35 | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value, 200,000,000 authorized as of December 31, 2025 and 2024, respectively; 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value, 1,000,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 126,469,610 and 126,106,176 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 13,000 | 13,000 | 13,000 | 12,000 | 12,000 | |
| Additional paid-in capital | 489 | 482 | 468 | 455 | 444 | |
| Accumulated other comprehensive income | 243,000 | 57,000 | −255,000 | −2 | −184,000 | |
| Accumulated deficit | −332 | −273 | −202 | −139 | −81 | |
| Total stockholders equity | 157 | 209 | 265 | 315 | 364 | |
| Total liabilities and stockholders equity | 191 | 243 | 306 | 350 | 398 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 7 | 13 | 12 | 10 | 8 | |
| Amortization of operating lease right-of-use assets | 5 | 4 | 4 | 2 | 2 | |
| Depreciation | 2 | 2 | — | — | — | |
| In-process research and development | 0 | 760,000 | 0 | — | — | |
| Amortization (accretion) of premiums (discounts) on securities, net | −1 | −3 | −3 | −890,000 | 183,000 | |
| Prepaid expenses and other assets | 544,000 | 666,000 | −821,000 | 756,000 | −3 | |
| Accounts payable | −69,000 | −578,000 | 393,000 | −561,000 | 1 | |
| Accrued expenses and other liabilities | 629,000 | −1 | 417,000 | 409,000 | 2 | |
| Operating lease liabilities | −5 | −4 | −3 | −1 | −788,000 | |
| Net cash used in operating activities | −51 | −59 | −52 | −46 | −39 | |
| Proceeds from maturities of securities | 109 | 155 | 72 | 163 | 85 | |
| Purchases of securities | −72 | −86 | −113 | −187 | −222 | |
| Purchases of property and equipment | −1 | −2 | −2 | −2 | −2 | |
| Cash paid in connection with asset acquisition | 0 | −760,000 | 0 | — | — | |
| Net cash provided by investing activities | 35 | 66 | −44 | −26 | −139 | |
| Proceeds from exercise of stock options | 58,000 | 620,000 | 104,000 | 330,000 | 167,000 | |
| Proceeds from issuance of common stock under employee stock purchase plan | 156,000 | 524,000 | 264,000 | 232,000 | 0 | |
| Net cash provided by financing activities | 214,000 | 1 | 368,000 | 562,000 | 327 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | −15 | 8 | −95 | −71 | 149 | |
| Acquisitions of property and equipment included in accounts payable | 99,000 | 74,000 | 148,000 | 174,000 | 64,000 | |
| Remeasurement of lease liabilities and right-of-use assets | 4 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Nautilus Biotechnology, Inc.'s CIK number?
Nautilus Biotechnology, Inc.'s SEC CIK number is 0001808805 (1808805). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Nautilus Biotechnology, Inc.'s SEC filings?
All of Nautilus Biotechnology, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Nautilus Biotechnology, Inc. last report earnings?
Nautilus Biotechnology, Inc. (NAUT) most recently filed an earnings 8-K with the SEC on Apr 28, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001808805-26-000015). This is Nautilus Biotechnology, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Nautilus Biotechnology, Inc.'s most recent earnings 8-K?
Nautilus Biotechnology, Inc.'s latest earnings 8-K (Item 2.02) was filed Apr 28, 2026 under accession 0001808805-26-000015. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Nautilus Biotechnology, Inc.'s latest earnings 8-K →
Look up any company's CIK number →